Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis.
Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo.
This study will enroll approximately 100 adult patients.
Subjects will come to the clinic on 6 occasions: at screening, baseline, week 2, week 4, week 8 (end of treatment/early termination) and week 10 (follow-up). The primary efficacy variable will be the IGA. Secondary efficacy variables will include IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis) Visual Analog Scale (VAS), EASI, BSA (Body Surface Area), POEM (Patient Orientated Eczema Measure), DLQI (Dermatology Life Quality Index).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oral DS107 2g | Experimental | Oral DS1072g, 4 x 500mg capsules administered orally once a day |
|
| Placebo | Placebo Comparator | Placebo capsules matching Oral DS107 capsules |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral DS107 | Drug |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Patients Achieving an Investigator's Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA at Week 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. | Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in IGA at Week 2, 4 and 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Climax, Ph.D. | Dignity Sciences Ltd. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dignity Sciences investigational site | Arlington Heights | Illinois | United States | |||
| Dignity Sciences investigational site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 11227040 | Background | Scollan ND, Choi NJ, Kurt E, Fisher AV, Enser M, Wood JD. Manipulating the fatty acid composition of muscle and adipose tissue in beef cattle. Br J Nutr. 2001 Jan;85(1):115-24. doi: 10.1079/bjn2000223. | |
| 19275928 | Background | Kawashima H, Toyoda-Ono Y, Suwa Y, Kiso Y. Subchronic (13-week) oral toxicity study of dihomo-gamma-linolenic acid (DGLA) oil in rats. Food Chem Toxicol. 2009 Jun;47(6):1280-6. doi: 10.1016/j.fct.2009.03.001. Epub 2009 Mar 9. |
Not provided
Not provided
A total of 102 patients were randomised. Patients were randomised (1:1) at baseline visit to either receive Oral DS107 capsules (2 g) or Placebo once daily for 8 weeks in a fasting state (minimum 8 hour fast).
The study was conducted in 2 countries at 17 sites.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Placebo capsules matching Oral DS107 capsules |
| FG001 | Oral DS107 2g | Oral DS1072g, 4 x 500mg capsules administered orally once a day |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety Population - The safety population was defined as all randomised patients who received at least one dose of the medication. Analysis was done according to the actual treatment patients received.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Placebo capsules matching Oral DS107 capsules |
| BG001 | Oral DS107 2g | Oral DS107 2g, 4 x 500mg capsules administered orally once a day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Patients Achieving an Investigator's Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA at Week 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses. | Posted | Number | Proportion of participants | Week 8 |
|
Up to 14 weeks.
An adverse event was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship with this treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Placebo capsules matching Oral DS107 capsules. | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pericardial effusion | Cardiac disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Dignity Sciences Ltd | +353 1 2933590 | dsbiopharma.regulatory@dsbiopharma.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 22, 2015 | Aug 3, 2022 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 19, 2015 | Aug 3, 2022 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
| ID | Term |
|---|---|
| D015126 | 8,11,14-Eicosatrienoic Acid |
| D005780 | Gelatin |
| D008899 | Mineral Oil |
| ID | Term |
|---|---|
| D015777 | Eicosanoids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
|
|
| Baseline, Week 2, Week 4 and Week 8 |
| Change From Baseline in Eczema Area and Severity Index (EASI) at Week 2, 4 and 8. | EASI quantifies the severity of a patient's AD based on both lesion severity and the percent of BSA affected. The EASI is a composite score ranging from 0-72 that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately, half points are permitted) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The severity of each sign is assessed using a 4-point scale (half points are permitted):
A decrease in EASI score indicates a positive outcome for the participant. | Baseline, Week 2, Week 4 and Week 8 |
| Proportion of Patients Achieving at Least a 1-point Decrease in IGA at Week 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. | Up to 8 weeks. |
| Change From Baseline in the Patient Orientated Eczema Measure (POEM) at Week 2, 4 and 8. | The Patient-Oriented Eczema Measure (POEM) is a self-assessment of disease severity by the patient. POEM has a maximum value of twenty-eight based on the patient's response to seven questions scored according to the following scale:
POEM scale ranges from 0 to 28. 0 to 2 = clear or almost clear. 3 to 7 = mild eczema. 8 to 16 = moderate eczema. 17 to 24 = severe eczema. 25 to 28 = very severe eczema. Lower scores on the scale represent a better outcome for the patient. | Baseline, Week 2, Week 4 and Week 8 |
| Change From Baseline in the Dermatology Life Quality Index (DLQI) Score at Week 2, 4 and 8. | The DLQI is a simple 10-question validated questionnaire measuring the impact of a patients skin problem over a 1 week period, which was completed at each visit, except screening. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30. | Baseline, Week 2, Week 4 and Week 8 |
| Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 2, 4 and 8. | The SCORAD grading system was developed by the European Task Force on Atopic Dermatitis and has been a standard tool to assess the AD severity in clinical studies. Six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) was selected to evaluate the AD severity. The intensity of each item is graded using a 4-point scale:
| Baseline, Week 2, Week 4 and Week 8 |
| Change From Baseline in the Patient's Visual Analog Scale (VAS) Pruritus Score at Week 2, 4 and 8. | The pruritus severity score was recorded with the SCORAD measurement and was evaluated as a separate endpoint. This was evaluated by asking subjects to indicate on the 10-cm scale (0-10) of the assessment form the point corresponding to the average value for the last three days/nights. A lower score represents a better outcome for the patient. | Baseline, Week 2, Week 4 and Week 8 |
| Change From Baseline in Body Surface Area (BSA) at Week 2, 4 and 8. | One patient's palm represents 1% of his/her total BSA. For all study visits except at screening, the BSA of involved skin will be measured with the SCORAD measurement and evaluated as a separate endpoint. | Baseline, Week 2, Week 4 and Week 8 |
| Number of Participants With TEAEs in Each Treatment Group | Number of participants with at least 1 TEAE. | Up to 14 weeks |
| West Dundee |
| Illinois |
| United States |
| Dignity Sciences investigational site | Warren | Michigan | United States |
| Dignity Sciences investigational site | Verona | New Jersey | United States |
| Dignity Sciences investigational site | New York | New York | United States |
| Dignity Sciences investigational site | Rochester | New York | United States |
| Dignity Sciences investigational site | Hazleton | Pennsylvania | United States |
| Dignity Sciences investigational site | Philadelphia | Pennsylvania | United States |
| Dignity Sciences investigational site | Calgary | Alberta | Canada |
| Dignity Sciences investigational site | Edmonton | Alberta | Canada |
| Dignity Sciences investigational site | Markham | Ontario | Canada |
| Dignity Sciences investigational site | Windsor | Ontario | Canada |
| Dignity Sciences investigational site | Drummondville | Quebec | Canada |
| Dignity Sciences investigational site | Montreal | Quebec | Canada |
| 7762522 | Background | Makrides M, Simmer K, Neumann M, Gibson R. Changes in the polyunsaturated fatty acids of breast milk from mothers of full-term infants over 30 wk of lactation. Am J Clin Nutr. 1995 Jun;61(6):1231-3. doi: 10.1093/ajcn/61.6.1231. |
| 19502748 | Background | Teraoka N, Kawashima H, Shiraishi-Tateishi A, Tanaka T, Nakamura J, Kakutani S, Kiso Y. Oral supplementation with dihomo-gamma-linolenic acid-enriched oil altered serum fatty acids in healthy men. Biosci Biotechnol Biochem. 2009 Jun;73(6):1453-5. doi: 10.1271/bbb.90112. Epub 2009 Jun 7. |
| 22411689 | Background | Tanaka T, Kakutani S, Horikawa C, Kawashima H, Kiso Y. Oral supplementation with dihomo-gamma-linolenic acid (DGLA)-enriched oil increases serum DGLA content in healthy adults. Lipids. 2012 Jun;47(6):643-6. doi: 10.1007/s11745-012-3664-3. Epub 2012 Mar 14. |
| Pregnancy |
|
| Lost to Follow-up |
|
| Adverse Event |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
Placebo capsules matching Oral DS107 capsules |
| OG001 | Oral DS107 2g | Oral DS1072g, 4 x 500mg capsules administered orally once a day |
|
|
|
| Secondary | Change From Baseline in IGA at Week 2, 4 and 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in Eczema Area and Severity Index (EASI) at Week 2, 4 and 8. | EASI quantifies the severity of a patient's AD based on both lesion severity and the percent of BSA affected. The EASI is a composite score ranging from 0-72 that takes into account the degree of erythema, induration/papulation, excoriation, and lichenification (each scored from 0 to 3 separately, half points are permitted) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The severity of each sign is assessed using a 4-point scale (half points are permitted):
A decrease in EASI score indicates a positive outcome for the participant. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | units on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Proportion of Patients Achieving at Least a 1-point Decrease in IGA at Week 8. | The IGA is a global assessment of the current state of the disease. It is a 6-point morphological assessment of overall disease severity and will be determined according to the following definitions: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe) and 5 (very severe). The scale uses clinical characteristics of erythema, infiltration, papulation and oozing/crusting as scoring guidelines for the overall severity assessment. A decrease in IGA indicates a positive outcome for the participant. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Number | Proportion of participants | Up to 8 weeks. |
|
|
|
| Secondary | Change From Baseline in the Patient Orientated Eczema Measure (POEM) at Week 2, 4 and 8. | The Patient-Oriented Eczema Measure (POEM) is a self-assessment of disease severity by the patient. POEM has a maximum value of twenty-eight based on the patient's response to seven questions scored according to the following scale:
POEM scale ranges from 0 to 28. 0 to 2 = clear or almost clear. 3 to 7 = mild eczema. 8 to 16 = moderate eczema. 17 to 24 = severe eczema. 25 to 28 = very severe eczema. Lower scores on the scale represent a better outcome for the patient. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | score on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in the Dermatology Life Quality Index (DLQI) Score at Week 2, 4 and 8. | The DLQI is a simple 10-question validated questionnaire measuring the impact of a patients skin problem over a 1 week period, which was completed at each visit, except screening. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | score on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 2, 4 and 8. | The SCORAD grading system was developed by the European Task Force on Atopic Dermatitis and has been a standard tool to assess the AD severity in clinical studies. Six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) was selected to evaluate the AD severity. The intensity of each item is graded using a 4-point scale:
| ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | score on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in the Patient's Visual Analog Scale (VAS) Pruritus Score at Week 2, 4 and 8. | The pruritus severity score was recorded with the SCORAD measurement and was evaluated as a separate endpoint. This was evaluated by asking subjects to indicate on the 10-cm scale (0-10) of the assessment form the point corresponding to the average value for the last three days/nights. A lower score represents a better outcome for the patient. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | score on a scale | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Change From Baseline in Body Surface Area (BSA) at Week 2, 4 and 8. | One patient's palm represents 1% of his/her total BSA. For all study visits except at screening, the BSA of involved skin will be measured with the SCORAD measurement and evaluated as a separate endpoint. | ITT Population - The Intent-to-treat (ITT) population consisted of all randomised patients. Analysis was done according to the randomised treatment. This population was used for all efficacy analyses | Posted | Mean | Standard Deviation | percentage of BSA | Baseline, Week 2, Week 4 and Week 8 |
|
|
|
| Secondary | Number of Participants With TEAEs in Each Treatment Group | Number of participants with at least 1 TEAE. | The safety population was defined as all randomised patients who received at least one dose of the medication. Analysis was done according to the actual treatment patients received. | Posted | Count of Participants | Participants | Up to 14 weeks |
|
|
|
| 51 |
| 1 |
| 51 |
| 23 |
| 51 |
| EG001 | Oral DS107 2g | Oral DS107 2g, 4 x 500mg capsules administered orally once a day | 0 | 51 | 0 | 51 | 37 | 51 |
| Pericarditis | Cardiac disorders | Systematic Assessment |
|
| Pneumonia | Infections and infestations | Systematic Assessment |
|
| Syncope | Nervous system disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal Pain Upper | Gastrointestinal disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal Discomfort | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal Pain | Gastrointestinal disorders | Systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | Systematic Assessment |
|
| Anal Pruritus | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Dry Mouth | Gastrointestinal disorders | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
|
| Faeces Discoloured | Gastrointestinal disorders | Systematic Assessment |
|
| Faeces Soft | Gastrointestinal disorders | Systematic Assessment |
|
| Gastroesophageal Reflux Disease | Gastrointestinal disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Seasonal Allergy | Immune system disorders | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | Systematic Assessment |
|
| Abscess | Infections and infestations | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | Systematic Assessment |
|
| Skin Bacterial Infections | Infections and infestations | Systematic Assessment |
|
| Upper Respiratory Tract Infection | Infections and infestations | Systematic Assessment |
|
| Foot Fracture | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Activated Partial Thromboplastin Time Abnormal | Investigations | Systematic Assessment |
|
| Blood Test Abnormal | Investigations | Systematic Assessment |
|
| Decreased Appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Back Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Dysgeusia | Nervous system disorders | Systematic Assessment |
|
| Restless Leg Syndrome | Nervous system disorders | Systematic Assessment |
|
| Proteinuria | Renal and urinary disorders | Systematic Assessment |
|
| Premenstrual Cramps | Reproductive system and breast disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Emphysema | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Nasal Congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Dermatitis Atopic | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D012596 |
| Scleroproteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D010577 | Petrolatum |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| Week 8 |
|
| Week 8 |
|
| Week 8 |
|
| Week 8 |
|
| Week 8 |
|
| Week 8 |
|
| Week 8 |
|